Oligonucleotide Synthesis Market

Thermo Fisher Scientific (US), IDT (US) and Biogen (US) are leading players in Oligonucleotide Synthesis Market

The global oligonucleotide synthesis market is projected to reach USD 8.2 billion by 2024 from USD 4.3 billion in 2019, at a CAGR of 13.7% during the forecast period. This market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.

The prominent players operating in this market include Agilent Technologies, Inc. (US), ATDBio Ltd. (UK), Bio-Synthesis, Inc. (US), BioAutomation Corporation (US), LGC Biosearch Technologies (US), Eurofins Genomics (Germany), Eurogentec (Belgium), GeneDesign, Inc. (Japan), GE Healthcare (US), GenScript, Inc. (US), Integrated DNA Technologies (IDT, US), Nitto Denko Avecia, Inc. (US), Sarepta Therapeutics (US), Thermo Fisher Scientific, Inc. (US), TriLink BioTechnologies (US), and Sigma-Aldrich Corporation (US) (a part of Germany-based Merck KGAA). Players in this market focused on partnerships, agreements, collaborations, expansions, and acquisitions to develop and expand their market presence. From 2016 to 2018, partnerships, collaborations, and agreements were the key growth strategies adopted by players such as Integrated DNA Technologies (acquired by Danaher Corporation), Merck KGaA, and Agilent Technologies.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific (US) is one of the leading players in the oligonucleotide synthesis market. The company has an exhaustive product portfolio, consisting of primers, probes, custom oligos, phosphoramidites, reagents, and custom oligo modification. The company has adopted various organic and inorganic growth strategies to strengthen its market position. For instance, in 2018, Thermo Fisher established a Bioprocess Design Center in China. In 2017, the company launched various products, including its Applied Biosystems NGM Detect PCR Amplification Kit, QuantStudio 5 Real-Time PCR System, and Ion AmpliSeq. Also, Thermo Fisher has a major focus on R&D, and invested USD 0.97 billion and USD 0.89 billion in R&D in 2018 and 2017, respectively. To increase the awareness about its products and offerings, the company has a strong promotional strategy and participates in various trade exhibitions, seminars, and workshops. These factors, coupled with its strong sales force in over 180 countries, have made Thermo Fisher one of the leading players in the oligonucleotide synthesis market.

IDT (US) (acquired by Danaher Corporation) holds a dominant position in the oligonucleotide synthesis market. The strong position of the company in this market can be attributed to its robust product portfolio and strong brand recognition. The company’s primary business is the production of custom oligonucleotides for molecular biology applications. IDT pursues product launches as its key growth strategy. For instance, in July 2017, it launched the Alt-R S.p. HiFi Cas9 Nuclease 3NLS enzyme (Cas9 enzyme variant). Similarly, in February 2017, IDT launched the Cpf1-based CRISPR genome editing system. It is the first genomics company to launch and develop a complete ribonucleoprotein-based Cpf1 CRISPR system, thereby enhancing its product portfolio and increasing its offerings for molecular biology researchers. Currently, IDT serves more than 100,000 life sciences researchers and produces more than 65,000 nucleic acids per day.

Biogen (US) is one of the leading players in oligonucleotide synthesis therapeutics market in 2017. This can be attributed to the launch of SPINRAZA in 2017. SPINRAZA is the first and only approved treatment for SMA (Spinal Muscular Atrophy). In 2019, SPINRAZA (nusinersen) was approved by the China National Medical Products Association (NMPA) for the treatment of 5q spinal muscular atrophy (SMA), expanding the company’s presence in China. The company has its oligonucleotide synthesis manufacturing (OSM) facility in North Carolina, which is utilized for manufacturing antisense oligonucleotide drugs like SPINRAZA and other antisense oligonucleotide drug candidates, which are currently in the pipeline.

Related Reports:

Oligonucleotide Synthesis Market by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type (Custom, Pre Design), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology) - Global Forecast to 2024

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
BT 2680
RI Published ON
4/26/2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved